Colorectal cancer remains one of the most commonly diagnosed malignancies worldwide, and its rising incidence in younger adults has baffled oncologists for more than a decade. While established risk factors such as age, genetics, physical inactivity, and diets heavy in red and processed meat are well documented, researchers have increasingly turned their attention to ultra-processed foods (UPFs) — industrial formulations manufactured from substances derived from foods, combined with cosmetic additives including emulsifiers, colorants, sweeteners and stabilizers. The NOVA classification system, which sorts foods according to their degree of industrial processing, has allowed epidemiologists to track consumption patterns, and the data reveal a dramatic global shift. Systematic reviews show that in some countries UPFs now account for more than half of daily caloric intake, and consumption trends continue to climb in regions as diverse as Europe, Asia and the Americas. This nutritional transition, the authors note, has coincided with rising rates of obesity, metabolic syndrome and colorectal cancer, prompting scientific scrutiny of the additives that give UPFs their signature properties.

Emulsifiers occupy a central place in that scrutiny. These molecules possess both water-loving and fat-loving regions, allowing them to bind oil and water into stable mixtures that would otherwise separate. Lecithins, mono- and diglycerides of fatty acids, polysorbate 80, carboxymethylcellulose, carrageenan and related compounds are added to thousands of products, from mayonnaise and margarine to plant-based milks and processed meats. Regulatory agencies in the United States and the European Union have long deemed these substances safe at approved concentrations, and industry reviews have generally supported that assessment. Yet the new review synthesizes a growing body of evidence suggesting that the question of emulsifier safety cannot be answered by traditional toxicology alone, because these additives interact with the trillions of microbes that inhabit the human gut — an ecosystem whose disruption, known as dysbiosis, is increasingly implicated in chronic disease.

The mechanistic case against emulsifiers begins with the mucus layer, the gel-like barrier that separates gut bacteria from the epithelial cells lining the intestine. In a healthy gut, this layer maintains a critical physical separation; most commensal bacteria live in the outer mucus, while the inner, densely packed layer keeps microbial products away from host tissue. Experimental work summarized in the review indicates that emulsifiers can alter the structure and transport properties of intestinal mucus, effectively thinning this defensive front. When the barrier is compromised, bacterial components such as lipopolysaccharide and flagellin gain access to the epithelial surface, triggering pattern-recognition receptors and activating inflammatory signaling cascades — most notably the NF-κB pathway, a master switch of intestinal inflammation whose chronic activation is a recognized feature of colitis-associated carcinogenesis.

The microbiome itself is transformed in the process. Landmark animal studies published in Nature in 2015 demonstrated that mice consuming water supplemented with common emulsifiers such as polysorbate 80 and carboxymethylcellulose developed profound shifts in microbial composition, including an expansion of bacteria capable of degrading mucus and an encroachment of microbes closer to the epithelium. These microbial changes drove low-grade intestinal inflammation and, over time, metabolic syndrome. Later research extended the findings, showing that emulsifier-exposed mice exhibited increased colitis severity, and that in genetically susceptible models, emulsifier consumption promoted the development of intestinal tumors. Crucially, the effects were not uniform: the impact of a given emulsifier depended on the composition of each animal’s resident microbiota, helping to explain why some individuals may be more vulnerable than others.

Human evidence, while more limited, is mounting. An ex vivo study using fecal samples from healthy donors found that several dietary emulsifiers directly altered human microbiota composition and gene expression in ways that potentiated intestinal inflammation, with marked person-to-person variability. More definitive was a randomized controlled-feeding trial published in Gastroenterology, in which healthy volunteers consumed carboxymethylcellulose at levels consistent with a high-UPF diet. The intervention shifted the participants’ microbiota toward an inflammatory profile, reduced microbial diversity, and encroached bacteria on the epithelium; metabolomic analysis revealed corresponding changes in short-chain fatty acids and other microbial products. Additional randomized work with carrageenan — a seaweed-derived emulsifier — suggested that even in people with quiescent ulcerative colitis, exposure could influence inflammatory markers and gastrointestinal symptoms, raising concern for patients whose intestinal barriers are already compromised.

Perhaps the most provocative findings come from large prospective human cohorts. The French NutriNet-Santé study, which follows more than 100,000 adults, published results in PLoS Medicine in 2024 linking higher intake of specific food additive emulsifiers to elevated overall cancer risk, with suggestive associations for several emulsifier classes and breast cancer in particular. While observational data of this kind cannot establish causation — people who eat more UPFs differ from others in many dietary and lifestyle respects — the findings align closely with the mechanistic literature and have intensified calls for regulatory reevaluation. The review also highlights disturbing animal data on developmental programming: offspring of mice fed emulsifiers during pregnancy and lactation showed metabolic and neuropsychological alterations, and emulsifier exposure accelerated the development of type 1 diabetes in genetically prone mice, suggesting that consequences may extend far beyond the gut of the individual consumer.

So how might emulsifier-induced dysbiosis translate specifically into colorectal cancer? The review lays out a plausible sequence. Barrier erosion allows bacterial penetration; the resulting chronic inflammation generates reactive oxygen and nitrogen species that damage epithelial DNA and drive compensatory cell proliferation. Dysbiosis simultaneously favors tumor-promoting species — the best-characterized being Fusobacterium nucleatum, an anaerobe enriched in colorectal tumors that has been shown to promote chemoresistance by modulating autophagy in cancer cells. At the same time, a depleted, inflammation-altered microbiota produces less butyrate and other short-chain fatty acids, the protective metabolites that normally nourish colonocytes, reinforce tight junctions and restrain immune overreaction. The net effect is an environment in which damaged cells survive, proliferate and evade immune surveillance — the essential ingredients of carcinogenesis. Experimental work dating back decades, including studies showing that germ-free animals can be protected from certain tumor-inducing chemicals, laid the conceptual foundation: the microbiota is not a bystander in colon cancer but an active participant whose diet-driven manipulation matters.

The authors are careful to frame their conclusions as a call for research rather than a definitive verdict. Observational studies confounded by overall dietary patterns, strain differences in animal models, the vast heterogeneity among emulsifier types, and person-to-person microbiome variability all complicate the picture. Some additive-safety reviews have concluded that current exposures pose no demonstrable risk. Nonetheless, the convergence of animal experiments, human feeding trials and prospective cohort data has, in the authors’ view, reached a threshold that warrants action on two fronts: the identification of demonstrably safe food additives, and the development of targeted interventions — including microbiome-modulating strategies, fermented foods, dietary fiber restoration and whole-food-based approaches — aimed at restoring gut homeostasis in vulnerable populations.

For consumers, the practical implications are pragmatic rather than alarmist. Reading ingredient labels for polysorbate 80, carboxymethylcellulose and carrageenan; substituting minimally processed foods for UPF staples where feasible; and emphasizing fiber-rich and fermented foods that support microbial diversity are all measures consistent with existing dietary guidance. For regulators, the review adds colorectal cancer to the growing list of outcomes — metabolic syndrome, inflammatory bowel disease, autoimmune conditions — that must be weighed in reevaluating food additive approvals. As the authors conclude, understanding the relationship among diet, emulsifiers and gut microbiota can guide dietary recommendations and regulatory policies to reduce colorectal cancer risk. Given that ultra-processed foods now supply such a large share of global calories, even a modest effect on cancer risk would translate into a substantial public health burden — one that may, at least in part, be preventable through the reformulation of the foods billions of people eat every day.

Professor Gilmore’s authoritative analysis underscores a fundamental truth: the forces driving environmental degradation and those harming human health are not discrete issues but are integrally linked, upheld by identical corporate behaviors and strategies. Industries such as fossil fuels, ultra-processed foods, alcohol, and tobacco wield considerable influence, systematically employing tactics designed to mislead scientific discourse, capture regulatory bodies, and lobby against effective legislation. These practices perpetuate a cycle wherein corporate profits are prioritized over climate sustainability and population well-being, hindering transformative policies and interventions.

The report dismantles the efficacy of voluntary initiatives and public-private partnerships touted by commercial actors, framing them instead as corporate strategies that deftly mask conflicts of interest and dilute accountability. Professor Gilmore cautions that self-regulation or government collaborations with these industries offer an illusion of progress while often entrenching corporate agendas within public policy frameworks. She draws parallels to the historical trajectory of tobacco control, where robust binding regulations and the protection of policymaking from corporate interference were instrumental in achieving public health victories.

From an economic standpoint, Professor Gilmore challenges the pervasive narrative that regulation imposes undue burdens on economic growth. She elucidates that the true economic calculus must incorporate the extensive costs inflicted by commercially driven climate and health damage—costs that far outweigh those associated with proactive regulatory measures. The report advocates for governments to rescind harmful subsidies, realign fiscal and trade policies with climate and health goals, and insulate policy processes from corporate capture, thereby fostering resilient systems that prioritize societal welfare.

Integral to this discourse is the imperative of governance innovation, where transparency, accountability, and independent monitoring form the pillars of effective public health and environmental policy. Professor Gilmore argues that rebuilding regulatory frameworks—rooted in empirical evidence and free from corporate distortion—is paramount to curbing the influence wielded by multinational corporations across sectors. This reimagined governance architecture, she asserts, will be critical to balancing the power asymmetry between global corporate entities and public authorities.

Professor Gilmore’s contributions to the WHO Pan-European Commission illustrate a rigorous examination of the systemic barriers that commercial determinants pose to health equity and environmental protection. Her work, supported by the WHO Council on the Economics of Health for All, identifies recurring corporate tactics including the manufacture of doubt through skewed scientific research, systematic lobbying to weaken regulatory efforts, and leveraging corporate social responsibility to evade stringent oversight. This engagement provides a comprehensive blueprint for deconstructing corporate interference and enhancing public policy integrity.

The conceptual framework underpinning Professor Gilmore’s advocacy reveals how commercial interests exploit regulatory loopholes and fragment policymaking processes to preserve business as usual. Her insights extend beyond criticism, outlining constructive pathways for governments to enact binding regulations that align economic activities with the urgent imperatives of climate resilience and public health promotion. This paradigm shift is posited as not merely desirable but essential for the sustainability of future generations and planetary ecosystems.

At the heart of these findings lies the pivotal assertion that effective regulation must transcend incrementalism and voluntary compliance. Professor Gilmore emphasizes that enforceable, transparent, and science-driven policies are indispensable to dismantling the entrenched influence of multinational corporations, thereby catalyzing systemic change. This position aligns with a growing global consensus that sustainable development strategies must integrate stringent oversight of commercial determinants to realize equitable health outcomes and safeguard environmental integrity.

Furthermore, Professor Gilmore situates her research within broader multidisciplinary collaborations, including the Local Health Global Profits consortium, which unites leading UK research institutions to interrogate and address commercial determinants at the municipal governance level. This integrative approach highlights the vital role of localized policy interventions in complementing national and international regulations, underscoring the complexity and scale of the challenge.

Expertise in public health policy, environmental governance, and climate action converge in Professor Gilmore’s innovative research agenda, positioning her at the forefront of efforts to reconceptualize the relationship between economic development and planetary health. Her urgent message to European policymakers encapsulates a transformative ethos: that safeguarding health and climate for present and future generations hinges on disentangling policy frameworks from the undue influence of powerful commercial actors.

In sum, Professor Anna Gilmore’s evidence-based advocacy and comprehensive critique presented to the Pan-European Commission on Climate and Health illuminate a critical path forward—one in which governments must adopt rigorous regulatory frameworks to confront and mitigate the pervasive influence of commercial determinants. This public health and environmental imperative demands immediate, integrated policy action to align economic systems with the profound challenges of climate change and human well-being, marking a potentially decisive turning point in Europe’s response to these intertwined crises.

Subject of Research: Commercial determinants of health, climate policy, and public health governance

Article Title: Leading Public Health Expert Calls for Regulatory Revolution to Tackle Climate and Health Crises in Europe

News Publication Date: 17 May 2026

Web References:

• Pan-European Commission on Climate and Health report: https://www.who.int/europe/groups/pan-european-commission-on-climate-and-health
• Local Health Global Profits (LHGP): https://www.phiuk.org/local-health-global-profits

Image Credits: Laurie Lapworth / University of Bath

Keywords: Public policy, Climate policy, Environmental policy, Health care policy, Regulatory affairs, Commercial determinants of health, Public health governance, Sustainability, Tobacco control, Fossil fuel industry, Corporate influence, Climate and health integration

Ultra-processed foods are defined by their complex manufacturing processes, transforming natural foods through multiple stages of industrial refinement. These products typically contain elevated levels of added sugars, sodium, unhealthy fats, and a variety of food additives including preservatives, colorants, and flavor enhancers. Despite their often palatable taste and convenience, these foods are nutritionally poor, characterized by high caloric content but low in essential nutrients such as dietary fiber, vitamins, and minerals. This qualitative imbalance forms the biochemical substrate upon which many pathophysiological conditions develop.

Dr. Xiao Liu of Sun Yat-sen Memorial Hospital elaborated on the mechanistic underpinnings connecting ultra-processed food consumption to deleterious health effects. The dysregulation of lipid metabolism precipitates atherogenic profiles, fostering cardiovascular disease. Concurrently, perturbations in the gut microbiota composition disrupt intestinal homeostasis, influencing systemic inflammatory pathways. This microbial imbalance can exacerbate immune activation, augment oxidative stress responses, and impair insulin sensitivity—pathways integrally linked to obesity, metabolic syndromes, and type 2 diabetes mellitus. These complex interrelations underscore the multifactorial nature of diet-induced chronic diseases.

The analysis encompassed 41 prospective cohort studies from diverse regions including the Americas, Europe, Asia, and Oceania, collectively involving 8,286,940 adults aged 18 years and older. This breadth confers substantial statistical power and heterogeneity, enabling generalized inferences regarding ultra-processed foods and health. The Nova classification system was uniformly employed across studies to categorize food items, ensuring methodological consistency. Nova delineates ultra-processed foods as industrially manufactured formulations predominantly derived from substances extracted or reconstituted from whole foods, subjected to intensive multi-step processing.

Quantitative findings from this systematic review reveal staggering risk increments concomitant with increased daily intake of ultra-processed foods. For every additional 100 grams consumed per day, the risk of developing hypertension surges by approximately 14.5%, cardiovascular events by 5.9%, and cancer by 1.2%. More alarmingly, digestive diseases see a 19.5% rise, and all-cause mortality climbs by 2.6%. Beyond these, correlations also emerged between ultra-processed food intake and psychiatric comorbidities such as depression and anxiety, suggesting systemic neuroimmune impacts perhaps mediated via gut-brain axis dysregulation.

To evaluate evidence robustness, researchers applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. This appraisal yielded high to moderate certainty levels for the majority of health outcomes, reinforcing the credibility of observed associations. An exception was metabolic syndrome and diabetes, for which only low certainty was assigned, indicating the need for further targeted research. This hierarchical assessment guides clinicians and policymakers in prioritizing intervention strategies founded on the most reliable data.

Clinical implications stemming from this research are profound. Physicians and healthcare providers bear the responsibility to communicate effectively the risks inherent in frequent consumption of ultra-processed foods. Their typical composition—excessive sugars, sodium, and unhealthy fats, coupled with scant fiber and protective micronutrients—constitutes a maladaptive nutritional profile exacerbating chronic disease trajectories. Importantly, evidence suggests a dose-response relationship wherein health risks amplify in proportion to ultra-processed food intake, underscoring the potential benefits of even modest reductions.

On a public health scale, the findings advocate for robust policy interventions to curtail ultra-processed food consumption globally. Regulatory measures such as stringent food labeling laws could mandate transparent disclosure of all ingredients, particularly artificial additives, empowering consumers to make informed dietary choices. Governments might consider taxation strategies or marketing restrictions aimed at reducing accessibility and appeal of these products. Parallelly, public health campaigns promoting minimally processed foods with high nutrient density could foster healthier eating patterns aligned with cultural and regional dietary preferences.

The limitations of this research lie partly in variability among definitions and thresholds of ultra-processed foods, which may affect direct comparability across included studies. Nevertheless, the collective evidence transcends these discrepancies, highlighting a coherent pattern of risk. The research also pivots attention beyond avoidance strategies, emphasizing the importance of embracing whole foods and established dietary models such as the Mediterranean or DASH diets. These dietary patterns are rich in unprocessed or minimally processed foods, abundant in phytochemicals, fibers, and essential micronutrients that collectively mitigate inflammation and oxidative stress.

Future investigations should prioritize longitudinal, high-quality randomized controlled trials to delineate causality and underlying biological mechanisms with greater precision. Additionally, research exploring sociocultural determinants of ultra-processed food consumption could inform tailored public health interventions. Understanding how socioeconomic factors, food environments, and behavioral drivers influence dietary choices remains pivotal to curbing the rising tide of chronic disease linked to these dietary exposures.

In summary, this comprehensive synthesis underscores the pressing need to reconsider the role of ultra-processed foods in contemporary diets. The dose-dependent relationship between their consumption and a spectrum of adverse health outcomes demands urgent attention from clinicians, researchers, and policymakers alike. Transitioning towards diets emphasizing nutrient-dense, culturally sensitive whole foods represents a pragmatic, evidence-based path to mitigating the global burden of cardiometabolic, oncologic, and digestive diseases—and ultimately enhancing population health outcomes worldwide.

Subject of Research: Health impacts of ultra-processed food consumption
Article Title: Consumption of Ultra-Processed Foods Significantly Elevates Risk of Hypertension, Cardiovascular Disease, and Mortality, New Study Shows
News Publication Date: May 9-11, 2024
Web References:

• https://www.acc.org/Education-and-Meetings/Meetings/Meeting-Items/2024/07/03/2025-Asia
• https://www.ACC.org
  Keywords: Ultra-processed foods, Cardiovascular disease, Hypertension, Cancer, Digestive diseases, Mortality, Nutrition, Public health, Dietary patterns, Gut microbiota, Systemic inflammation, Epidemiology